GET DAILY SIGNALSChampions Oncology (CSBR): Steady Operational Gains Keep the Stock in Focus
Key Takeaways
- Champions Oncology (CSBR) traded near $4.83 in early November 2026, roughly 1% below its level about 30 days earlier, reflecting a largely range-bound micro-cap profile.
- Fiscal Q1 2027 revenue rose about 9% year over year to $15.2 million, with adjusted EBITDA positive for a fifth consecutive quarter.
- Data licensing revenue in the most recent quarter surpassed the total recorded for the entire prior fiscal year, underscoring a shift toward higher-margin data monetization.
- The company continues to diversify its translational oncology platform, including expanded radiopharmaceutical development capabilities.
- Investors tracking CSBR should monitor the sustainability of data licensing momentum alongside core research-services revenue and margin trends.
- For more detail, explore the company's Price Targets, Earnings, and Forecast pages to review additional metrics and outlooks.
Where CSBR Stands in the Current Market
Champions Oncology (CSBR) is a small-cap biotechnology services company with a market capitalization near $67 million. The stock has traded in a relatively tight band in recent weeks, closing around $4.83 in early November 2026, marginally below its level about 30 days earlier. Over a longer horizon, the shares have moved within a wide 52-week range of approximately $4.59 to $8.31, reflecting the volatility typical of micro-cap healthcare names with limited trading liquidity.
Sentiment around the company has been shaped by steady operational improvement rather than dramatic catalysts. Revenue growth, consistent positive adjusted EBITDA, and a growing data licensing business have supported a cautious-but-constructive view among followers of the stock, even as the broader small-cap biotechnology sector remains sensitive to shifts in risk appetite and interest-rate expectations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Business Overview and Competitive Position
Champions Oncology is a technology-enabled oncology research company headquartered in Hackensack, New Jersey. The company provides drug discovery and development solutions to pharmaceutical and biotechnology clients through a proprietary bank of roughly 1,500 patient-derived xenograft (PDX) models and its TumorGraft platform, which supports translational oncology research services.
Beyond core research services, Champions monetizes its clinically annotated data through licensing and its Lumin Bioinformatics software-as-a-service platform, giving clients access to proprietary oncology datasets. This diversification is central to the company's strategy, as data licensing and software carry higher margins than traditional preclinical services. The company's competitive position rests on the depth and clinical annotation of its PDX collection and its integrated computational and experimental platforms, which aim to accelerate oncology drug development for partners.
Recent Developments Driving the Stock
The most significant recent development was the company's fiscal first-quarter 2027 results, reported in September 2026. Revenue grew about 9% year over year to $15.2 million, gross margin reached approximately 50%, and adjusted EBITDA came in positive for a fifth consecutive quarter. Notably, data licensing revenue in the single quarter exceeded the total data licensing revenue recorded across the entire prior fiscal year, highlighting accelerating traction in the higher-margin segment.
Operationally, Champions also announced the expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities, extending its existing translational offerings. Management commentary emphasized improved study execution and cost discipline, which contributed to margin gains. These factors, combined with a debt-free balance sheet and a cash position of roughly $4.4 million at quarter-end, helped reinforce a more stable fundamental backdrop even as the share price remained range-bound. From what I see, this operational discipline is worth watching closely.
2026 Outlook and Key Areas to Monitor
Looking ahead, the key question for Champions Oncology is whether the recent surge in data licensing activity represents a durable, scalable revenue stream or a concentration of one-time transactions. Management has previously noted that data revenue can be lumpy and influenced by large, non-recurring deals, so investors should track the consistency of bookings and deferred revenue trends over multiple quarters.
Core research services will remain the foundation of the business, making study execution, customer retention, and gross-margin trajectory critical indicators. The continued build-out of radiopharmaceutical and imaging capabilities also positions the company to capture demand in an expanding therapeutic modality. Risks to monitor include customer concentration, the timing of large contracts, competition in the preclinical services market, and the company's modest cash position relative to its operating cash burn. As a micro-cap, CSBR's shares may also remain sensitive to liquidity and broader market risk sentiment.
Using AI Tools for Additional Perspective
I've found Tickeron's AI Trading Bots helpful for testing different approaches on stocks like this one. The platform lets users explore a range of automated strategies across various timeframes and risk parameters, which can add another layer of insight when evaluating names that trade in tight ranges. One thing that stands out is how these tools surface patterns that might not be obvious from fundamentals alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CSBR's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CSBR turned positive on October 27, 2026. Looking at past instances where CSBR's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 68 cases where CSBR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on CSBR as a result. In 89 of 116 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
Following a +2.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where CSBR advanced for three days, in 161 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
CSBR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CSBR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for CSBR entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.269) is normal, around the industry mean (3.498). P/E Ratio (-60.375) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (4.510) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.136) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. CSBR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CSBR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of advanced technology solutions and services for oncology drugs
Industry Biotechnology
Advertisement